Enhancing Patient Selection in Oncology: Clinical Validation of a Multi- Gene Expression Diagnostic to Predict Sensitivity to DDR Therapies
Time: 2:15 pm
day: Day Two
Details:
- Introduction to Allarity’s Drug Response Predictor (DRP)- a multi-gene expression diagnostic for selecting patients likely to benefit from DDR therapies
- Sharing key findings from the phase II advanced, recurrent ovarian cancer study showcasing the impact of Allarity’s novel PARP/ Tankyrase inhibitor, Stenoparib
- A discussion of Stenoparib’s potential in advanced ovarian cancer using the Stenoparib DRP to select patients for therapeutic benefit
